PYC Therapeutics (ASX:PYC) Total Assets: A$159.13 Mil (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
36 GF Score
Price A$1.65
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Total Assets?

PYC Therapeutics ASX:PYC +7.49% 36 Total Assets is A$159.13 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

PYC Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was A$159.13 Mil.

During the past 12 months, PYC Therapeutics's average Total Assets Growth Rate was 102.60% per year. During the past 3 years, the average Total Assets Growth Rate was 23.00% per year. During the past 5 years, the average Total Assets Growth Rate was 40.10% per year. During the past 10 years, the average Total Assets Growth Rate was 80.10% per year.

During the past 13 years, PYC Therapeutics's highest 3-Year average Total Assets Growth Rate was 214.90%. The lowest was -25.00%. And the median was 20.25%.

Total Assets is connected with ROA %. PYC Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -26.67%. Total Assets is also linked to Revenue through Asset Turnover. PYC Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

PYC Therapeutics  (ASX:PYC) Total Assets Explanation

Total Assets is connected with ROA %.

PYC Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-45.658/( (183.279+159.13)/ 2 )
=-45.658/171.2045
=-26.67 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PYC Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (183.279+159.13)/ 2 )
=0/171.2045
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PYC Therapeutics Total Assets Related Terms

PYC Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Total Assets Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.94 45.35 37.17 91.24 183.28

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.76 91.24 68.23 183.28 159.13
ASX:PYC
36GF Score
PYC Therapeutics Ltd ASX:PYC
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PYC Therapeutics's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=170.008+13.271
=183.28

PYC Therapeutics's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=147.328+11.802
=159.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$159.13 Mil mean?
PYC Therapeutics (ASX:PYC) has a Total Assets of A$159.13 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Total Assets too high?
PYC Therapeutics' current Total Assets is A$159.13 Mil. Overall, PYC Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Total Assets compare to VRTX and REGN?
PYC Therapeutics' Total Assets of A$159.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Total Assets is A$159.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Total Assets of A$159.13 Mil. The current Total Assets is A$159.13 Mil. PYC Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Total Assets is A$159.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
36GF Score

Get the complete analysis for ASX:PYC

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.65
Price